IBO - impact-biomedical-shows-mixed-performance-amid-high-investor-interest

Deep-Dive Due Diligence AI Generated Report on Impact BioMedical, Inc. (IBO)

Welcome to ScanScor. What you're reading is not just a stock summary -- it's a real-time, AI-generated due diligence session crafted from live news, financial data, insider trading activity, SEC filings, and live market momentum.

These reports are generated using OpenAI's GPT-based analysis engine, guided by tightly structured prompts and expert-level data ingestion. Every insight below was assembled to help you understand the forces behind today's market movers.

Disclaimer: This report is for informational purposes only. It does not constitute financial advice. Always do your own research before making any investment.

IBO_OUT_1 [2025-03-20 12:05:55 -0400] 2261 Bytes | 606 tokens | Cum: 606 tkns (7.58% of 8k)
==========================================================================

We need a winner today and it's already 12:05:52 PM on Thursday March 20, 2025 ET (UTC-0400) ... So let's find out if Impact BioMedical (IBO) is going up or if it's going nowhere fast. So, I pulled together a bunch of data for you to look over real fast. It's at 1.63 up from 0.53. Is there something here we can get excited about? Help me analyze.

Here's the first list of news for Impact BioMedical:

C1 - Feb-26-25 08:30AM - Impact Biomedical Inc. Announces Acquisition of Celios , Protecting People, Plants, and Animals from the World's Most Dangerous Pathogens With Clean-Room Air Quality
C2 - Feb-26-25 08:30AM 08:30AM - DSS, Inc. Announces Sale of Celios® to Impact BioMedical, Streamlining Portfolio for Strategic Growth
C3 - Jan-23-25 04:30PM - Impact BioMedical Inc. to Present at The Microcap Conference
C4 - Nov-19-24 08:00AM - Impact BioMedical Inc. Issues Shareholder Letter Highlighting Recent Achievements and Strategic Vision
C5 - Nov-18-24 07:00AM - Impact BioMedical Inc. (NYSEAmerican: IBO): Targeting Chronic Diseases with Patented Breakthroughs
C6 - Nov-11-24 07:30AM - Positioned for Growth: Impact BioMedical Inc.'s (NYSEAmerican: IBO) Push into Cancer and Immune Health
C7 - Oct-15-24 06:00AM - Impact BioMedical Inc. Announces Issuance of Canadian Patent for Linebacker Technology Targeting Inflammatory Disease
C8 - Oct-07-24 08:30AM - Impact BioMedical Inc. (NYSE American: IBO) Announces IPO Participation with Strong Support from Partners and Affiliates

ONLY 3 RULES for AI:
==============
1) I am a document retrieval system. You are the analyst-investigator.
2) You can request items from my lists to get more info on Impact BioMedical (IBO)
3) AFTER requesting and reading News and SEC filings you'll write a summary, set a score, high price target and headline.
Now, your response should be only 2 or 3 chars. You can say ex., C1, C2, etc., or NEX
The NEX command delivers the NEXt list of News/SEC/Metrics
There are several more lists that use our unified document retrieval system in subsequent prompts.
Your predictons will be compared to reality to rate your accuracy. Try to predict accurately. GOOD LUCK!
Please request a document, read, summarize and score. Say something like "C1".

IBO_IN_2 [2025-03-20 12:05:55 -0400] 2 Bytes | 2 tokens | Cum: 608 tkns (7.60% of 8k)
==========================================================================

IBO_OUT_3 [2025-03-20 12:05:59 -0400] 968 Bytes | 276 tokens | Cum: 884 tkns (11.05% of 8k)
==========================================================================

Showing C1 (chunk 1 of 4): C1:
**Impact Biomedical Inc. Announces Acquisition of Celios , Protecting People, Plants, and Animals from the World's Most Dangerous Pathogens With Clean-Room Air Quality**
Date: Feb-26-25 08:30AM
Source: (GlobeNewswire)
URL: https://www.globenewswire.com/news-release/2025/02/26/3032920/0/en/Impact-Biomedical-Inc-Announces-Acquisition-of-Celios-Protecting-People-Plants-and-Animals-from-the-World-s-Most-Dangerous-Pathogens-With-Clean-Room-Air-Quality.html

February 26, 2025 08:30 ET| Source:IMPACT BIOMEDICAL INCIMPACT BIOMEDICAL INC

HOUSTON, Feb. 26, 2025 (GLOBE NEWSWIRE) -- Impact BioMedical Inc. (NYSE American: IBO), a pioneering biotechnology company dedicated to discovering, developing, and patenting innovative healthcare solutions, today announced the acquisition of Celios®, a pioneering air purification technology company, in a strategic, all equity transaction valued at approxi

-- More? (MOR) or Next section? (NEX)

IBO_IN_4 [2025-03-20 12:05:59 -0400] 3 Bytes | 2 tokens | Cum: 886 tkns (11.07% of 8k)
==========================================================================

NEX

IBO_OUT_5 [2025-03-20 12:06:00 -0400] 978 Bytes | 294 tokens | Cum: 1180 tkns (14.75% of 8k)
==========================================================================

We present this news so you can catch the big movers from recently breaking news.
Here's a list of news articles you can literally read just by asking.
Usually the first item is the most important.

A1 - 2025-03-12T17:27:46Z - 12 Health Care Stocks Moving In Wednesday's Intraday Session - Baird Medical Investment (NASDAQ:BDMD...
A2 - 2025-03-04T07:54:54Z - Pre-market Movers: Interactive Strength, DocGo, DLocal, Iovance Biotherapeutics, Acadia Healthcare...
A3 - 2025-02-28T14:33:38Z - Pre-market Movers: TRNR, DCGO, DLO, IOVA, ACHC....
A4 - 2025-02-26T14:25:37Z - DSS, Inc. Announces Sale of Celios® to Impact BioMedical, Streamlining Portfolio for Strategic Growt...
A5 - 2025-02-26T13:33:07Z - Impact Biomedical Inc. Announces Acquisition of Celios®, "Protecting People, Plants, and ......

Request an article by its reference number. (Ex., "A1" gets the first item)
You may also say NEX to go to the next listing.
Response to this prompt limited to 3 chars.

IBO_IN_6 [2025-03-20 12:06:00 -0400] 2 Bytes | 2 tokens | Cum: 1182 tkns (14.77% of 8k)
==========================================================================

IBO_OUT_7 [2025-03-20 12:06:02 -0400] 967 Bytes | 293 tokens | Cum: 1475 tkns (18.44% of 8k)
==========================================================================

Showing A1 (chunk 1 of 3): A1:
**12 Health Care Stocks Moving In Wednesday's Intraday Session - Baird Medical Investment (NASDAQ:BDMD), CervoMed (NASDAQ:CRVO)**Date: 2025-03-12Source: {'uri': 'benzinga.com', 'dataType': 'news', 'title': 'Benzinga'}URL: https://www.benzinga.com/insights/movers/25/03/44283737/12-health-care-stocks-moving-in-wednesdays-intraday-sessionGainers CervoMed CRVO stock increased by 151.1% to $5.93 during Wednesday's regular session. The market value of their outstanding shares is at $48.9 million. OptimizeRx OPRX shares rose 35.74% to $5.62. The company's market cap stands at $103.5 million. As per the press release, Q4 earnings came out today. Healthcare Triangle HCTI shares increased by 26.86% to $0.41. The market value of their outstanding shares is at $2.6 million. HeartSciences HSCS stock increased by 19.86% to $3.5. The market value of their outstanding shares is at $3.4 million. Bair

-- More? (MOR) or Next section? (NEX)

IBO_IN_8 [2025-03-20 12:06:02 -0400] 3 Bytes | 2 tokens | Cum: 1477 tkns (18.46% of 8k)
==========================================================================

NEX

IBO_OUT_9 [2025-03-20 12:06:04 -0400] 968 Bytes | 285 tokens | Cum: 1762 tkns (22.02% of 8k)
==========================================================================

This is our final list of news.
News AI can literally read just by asking.
Don't miss the breaking news!

B1 - 2025-02-26T13:30:00Z - Impact Biomedical Inc. Announces Acquisition of Celios®, "Protecting People, Plants, and Animals from the World's Most Dangerous Pathogens With Clean-Room Air Quality"
B2 - 2024-12-12T20:56:00Z - Contractor Wins Prestigious Award for Exquisite Ornamental Staircase
B3 - 2024-10-25T11:00:00Z - ImPact Biotech to Present Updated Interim Phase 3 Data from ENLIGHTED Study of Padeliporfin VTP in Low Grade UTUC at EMUC 2024
B4 - 2024-10-15T10:00:00Z - Impact BioMedical Inc. Announces Issuance of Canadian Patent for Linebacker™ Technology Targeting Inflammatory Disease
B5 - 2024-09-17T15:29:05Z - Impact BioMedical Inc. Announces the Closing of its Initial Public Offering

Request an article by its reference number. (Ex., "B1" gets the first item)
You can say NEX to go to the next listing.
Response limited to 3 chars.

IBO_IN_10 [2025-03-20 12:06:04 -0400] 2 Bytes | 2 tokens | Cum: 1764 tkns (22.05% of 8k)
==========================================================================

IBO_OUT_11 [2025-03-20 12:06:10 -0400] 777 Bytes | 181 tokens | Cum: 1945 tkns (24.31% of 8k)
==========================================================================

Showing B1 (chunk 1 of 1): B1:
**Impact Biomedical Inc. Announces Acquisition of Celios®, "Protecting People, Plants, and Animals from the World's Most Dangerous Pathogens With Clean-Room Air Quality"**Date: Unknown DateSource: Unknown SourceURL: https://www.benzinga.com/pressreleases/25/02/g43971463/impact-biomedical-inc-announces-acquisition-of-celios-protecting-people-plants-and-animals-from-thImpact Biomedical Inc. has acquired Celios®, a pioneering air purification technology company, in a strategic all-equity transaction. The acquisition aligns with Impact Biomedical's strategy to expand its portfolio with cutting-edge solutions that generate immediate revenue and reinforce its commitment to human health and wellness.

-- More? (MOR) or Next section? (NEX)

IBO_IN_12 [2025-03-20 12:06:11 -0400] 677 Bytes | 118 tokens | Cum: 2063 tkns (25.79% of 8k)
==========================================================================

Impact Biomedical Inc. has made a strategic decision to acquire Celios, an innovative air purification technology company. The acquisition was made through an all-equity transaction. This move is in line with Impact Biomedical's plans to broaden its range of solutions and generate immediate revenue. It also demonstrates their dedication to promoting human health and wellness. This development could potentially boost Impact Biomedical's market position and financial performance. However, the specifics of the deal, such as the acquisition price and expected financial impact, are not detailed in the report, which would be necessary to make a more comprehensive evaluation.

IBO_OUT_13 [2025-03-20 12:06:12 -0400] 1127 Bytes | 305 tokens | Cum: 2368 tkns (29.60% of 8k)
==========================================================================

This is our list of SEC filings.
Read it just by asking.
Don't miss breaking filings!

S1 - 2025-01-29 8-K Item 7.01 Regulation FD Disclosure

Frank D. Heuszel, the Companys Chf Exec Off, provided certain investor information, commencing on January 29, 2025. The slide package prepared by the Company for use in connection with these presentations is furnished herewith as Ex...

S2 - 2024-11-12 10-Q Impact BioMedical Inc and Subsidiaries

Condensed Cons Balance Sheets

September 30, 2024

(unaudited)

December 31, 2023 ASSETS Curr assets: Cash and cash equiv $ 2,668,000 $ 1,000 A/R, net - 128,000 Curr portion of notes receivable 142...

S3 - 2024-11-04 8-K Item 7.01 Regulation FD Disclosure

Mark Suseck, the Companys Chf Operating Off, provided certain investor information, commencing on November 4, 2024. The slide package prepared by the Company for use in connection with these presentations is furnished herewith as Exhibit...

Request filing by its reference number. (Ex., "S1" gets the first item)
You can say NEX to go to the next listing - but what fun is that?
Response limited to 3 chars.

IBO_IN_14 [2025-03-20 12:06:12 -0400] 2 Bytes | 2 tokens | Cum: 2370 tkns (29.62% of 8k)
==========================================================================

IBO_OUT_15 [2025-03-20 12:06:25 -0400] 846 Bytes | 197 tokens | Cum: 2567 tkns (32.09% of 8k)
==========================================================================

Showing S1 (chunk 1 of 1): S1:
Item 7.01 Regulation FD Disclosure

Frank D. Heuszel, the Companys Chief Executive Officer, provided certain investor information, commencing on January 29, 2025. The slide package prepared by the Company for use in connection with these presentations is furnished herewith as Exhibit 99.1. All of the information in the attached presentation is presented as of January 29, 2025, and the Company does not assume any obligation to update such information in the future.

The information included in this Form 8-K, as well as the exhibit referenced herein, shall not be deemed filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended....

-- More? (MOR) or Next section? (NEX)

IBO_IN_16 [2025-03-20 12:06:25 -0400] 1218 Bytes | 245 tokens | Cum: 2812 tkns (35.15% of 8k)
==========================================================================

As a financial analyst, I interpret this information as follows:

This document is a Form 8-K, which is a report that publicly traded companies must file with the U.S. Securities and Exchange Commission (SEC) to announce major events that shareholders should be aware of.

On January 29, 2025, the company's CEO, Frank D. Heuszel, provided investor information through a series of presentations. The slides used in these presentations have been attached as Exhibit 99.1. However, the company has stated that it does not have any obligation to update the information presented in these slides in the future.

The document also clarifies that the information in this Form 8-K and its referenced exhibit should not be considered as filed for purposes of Section 18 of the Securities Exchange Act of 1934, nor should it be deemed incorporated by reference in any filing under the Securities Act of 1933.

This essentially means that the information provided in this document and the attached exhibit is not legally binding in terms of the Securities Exchange Act and the Securities Act. It's a disclosure for the investors' knowledge but it's not intended to serve as a legal document for the purposes of the named Acts.

IBO_OUT_17 [2025-03-20 12:06:42 -0400] 3880 Bytes | 1062 tokens | Cum: 3874 tkns (48.43% of 8k)
==========================================================================

This is our set of metrics.
Please analyze the numbers.

The next section covers any insider trading.
If this section is blank, it's because there've been no recent filings.

Now we've reached the end of the analysis.
You are now invited to make a summary analysis.
Please don't explain why you didn't have enough information.
Save that for the survey that comes last.

Finish the summary with two scores: MARKET_SCORE[] and PRICE_TARGET[]

If you calculate a 92% likelihood of an upward moves, say: MARKET_SCORE[92]
If you think the high today will be 50% higher, add to the price. Eg., If the price is $5.00, add 50%: PRICE_TARGET[$7.50]
PRICE_TARGET is the highest it is expected to rise today, so it cannot be less than the current price.
Please provide a thought-provoking take, 6-10 words, to use for the headline of this news story.
Like this: AI_RPT_HEADLINE: [6-10 words headline for news story from first summary paragraph]
Again, that is: 1) Brief Summary, 2) MARKET_SCORE, 3) PRICE_TARGET, and 4) AI_RPT_HEADLINE

[Company Financial Summary]
[Company Details]
Name: Impact BioMedical, Inc.
Market Cap: N/A
Shares Outstanding: N/A
Sector: PHARMACEUTICAL PREPARATIONS

[Financial Statements - Latest Quarter]
Total Assets: N/A
Total Liabilities: N/A
Total Equity: N/A
Revenue (Quarter): {'value': 0, 'unit': 'USD', 'label': 'Revenues', 'order': 100}
Net Income: {'value': 4241000.0, 'unit': 'USD', 'label': 'Net Income/Loss', 'order': 3200}
Earnings Per Share (EPS): N/A

[Price Metrics - Last 30 Days]
Latest Close: 1.6697
Average Volume: 182336.09
30-Day High: 2.12
30-Day Low: 0.53

[Detailed Financials: Q3 2024]
- Total Assets: $46,695,000.0
- Total Liabilities: $12,344,000.0
- Total Equity: $34,351,000.0
- Current Assets: $3,175,000.0
- Current Liabilities: $1,138,000.0

[Income Statement: Q3 2024]
- Revenue: $0
- Net Income: $4,241,000.0
- Operating Income: $-1,127,000.0
- Earnings Per Share (EPS): 0.37

[Cash Flow Statement: Q3 2024]
- Net Cash Flow: $2,666,000.0
==== END OF FINANCIAL REPORT ====

IBO_IN_18 [2025-03-20 12:06:42 -0400] 1484 Bytes | 343 tokens | Cum: 4217 tkns (52.71% of 8k)
==========================================================================

The financial metrics for Impact BioMedical, Inc., a pharmaceutical preparation company, suggest a mixed performance. The company has had a significant weekly performance, with a 164.10% increase. The company's short-term performance has also been strong, indicated by a 44.90% increase in the SMA20. However, it has struggled in the mid-to-long term horizon, as indicated by a -6.96% SMA200, -11.50% performance over the month, and a -23.71% performance over the quarter.

The company has a relatively low market capitalization of $20.35M and a low average volume of 27.25K, but an enormous relative volume of 255.03, indicating high investor interest. The company appears to have no sales growth over the past 5 years, and no sales or earnings surprises. The debt-to-equity ratio is fairly low at 0.26, suggesting a manageable level of debt, and the company has a positive return on equity of 4.01%, indicating efficient use of shareholder capital.

The company did not report any revenues for Q3 2024 but had a net income of $4,241,000.0. The total assets of the company stood at $46,695,000.0, with liabilities at $12,344,000.0, indicating a healthy financial position. Given these factors, despite some negative performance metrics, the company's financial health seems stable, and the high investor interest could potentially drive price increases.

MARKET_SCORE[70]
PRICE_TARGET[$2.50]

AI_RPT_HEADLINE: "Impact BioMedical Shows Mixed Performance Amid High Investor Interest."

IBO_OUT_19 [2025-03-20 12:06:44 -0400] 561 Bytes | 131 tokens | Cum: 4348 tkns (54.35% of 8k)
==========================================================================

Finally, if more data could have improved your confidence which would you have chosen? **Choose one option:**
-> X0 <- Nothing more would have helped my analysis
-> X1 <- More stock-specific news
-> X2 <- More SEC filings & insider data
-> X3 <- Broader sector & market news
-> X4 <- General market sentiment & AI confidence levels
-> X5 <- AI's past analysis on similar companies
-> X6 <- More financial metrics
-> X7 <- AI's past analysis on this exact company
-> X8 <- Something altogether different (explain...)

IBO_IN_20 [2025-03-20 12:06:44 -0400] 40 Bytes | 10 tokens | Cum: 4358 tkns (54.47% of 8k)
==========================================================================

-> X2 <- More SEC filings & insider data

IBO_IN_21 [2025-03-20 12:06:45 -0400] 126 Bytes | 29 tokens | Cum: 4387 tkns (54.84% of 8k)
==========================================================================

====================================
[2025-03-20 09:06:45] # Analysis Completed
Elapsed Time: 52.88 seconds